Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

OmniRE-seq: A Dual-Method Framework for Decoding RNA Editing Dynamics in Disease and Therapy

Created on 24 Oct 2026

Authors

Hang, Y., Liu, H., Li, W., Liu, P., Yang, J., Zhao, Y.

Abstract

RNA editing is a widespread post-transcriptional modification involved in transcriptome diversity and disease regulation. However, its quantification remains technically challenging. We present OmniRE-seq, a dual-framework combining RE-seq for bulk and scRE-seq for single-cell RNA-seq data, enabling multi-level quantification, differential analysis, and functional annotation of RNA editing. Using RE-seq, we profile editing alterations across diverse contexts -- including murine sepsis, MDS, drug-treated melanoma, and colorectal cancer -- demonstrating the utility of locus-, gene-, and burden-level metrics in capturing biologically meaningful differences. scRE-seq further resolves cell-type-specific editing patterns by aggregating cells of shared identity into pseudo-bulk units (Spots), enhancing editing signal while preserving cellular resolution in colorectal cancer. Integrated bulk and single-cell analysis identified convergent editing signals and therapeutic targets, exemplified in a mouse model of thymic atrophy treated with Ganoderma lucidum spores. Together, OmniRE-seq offers a standardized and scalable toolkit for dissecting RNA editing landscapes across resolution levels, advancing both mechanistic discovery and translational application in precision medicine.

Preprint server: bioRxiv
The authors list and abstract were imported from bioRxiv on 24 Oct 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this preprint? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 11
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement